Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letter to the Editor - Study Letter
2017:83:4;496-499
doi: 10.4103/ijdvl.IJDVL_96_16
PMID: 28540881

High B-cell-activating factor levels in endemic Tunisian pemphigus

Kaouthar Mejri1 , Maryam Kallel Sellami1 , Ines Rania Zaraa2 , Lilia Laadhar1 , Houria Lahmar1 , Mourad Mokni2 , Insaf Mokhtar3 , Bacima Fezza4 , Mondher Zitouni1 , Sondes Makni1
1 Department of Immunology, La Rabta Hospital, Tunis, Tunisia
2 Department of Dermatology, La Rabta Hospital, Tunis, Tunisia
3 Department of Dermatology, Habib Thameur Hospital, Tunis, Tunisia
4 Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia

Correspondence Address:
Maryam Kallel Sellami
Department of Immunology, La Rabta Hospital, Tunis 1007
Tunisia
How to cite this article:
Mejri K, Sellami MK, Zaraa IR, Laadhar L, Lahmar H, Mokni M, Mokhtar I, Fezza B, Zitouni M, Makni S. High B-cell-activating factor levels in endemic Tunisian pemphigus. Indian J Dermatol Venereol Leprol 2017;83:496-499
Copyright: (C)2017 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

B-cell-activating factor belonging to the tumor necrosis factor family plays a crucial role in B-cell development, immunoglobulin production and switch to the IgG, IgE and IgA subclasses. Excessive B-cell-activating factor rescues self-reactive B cells from anergy which may play a crucial role in the induction and development of autoimmunity. Previous reports have shown elevated serum B-cell-activating factor levels in patients with systemic lupus, Sjögren syndrome and rheumatoid arthritis.[1]

Pemphigus is an autoimmune intraepidermal blistering disease characterized by the presence of autoantibodies against desmoglein 1 in pemphigus foliaceus and desmoglein 3 in pemphigus vulgaris. Knowing that B-cell-activating factor pathway is involved in the generation of autoreactive B cells, we analyzed serum B-cell-activating factor levels in Tunisian pemphigus vulgaris and pemphigus foliaceus patients and correlated their levels with clinical presentation and autoantibody profile.[2]

This is a cross-sectional retrospective study on frozen samples at −80°C. Sera were obtained from 50 pemphigus foliaceus patients and 36 pemphigus vulgaris patients with a median age of 44 years (range 17–81). All patients fulfilled clinical and immunological criteria of pemphigus. Forty pemphigus foliaceus patients as well as 29 pemphigus vulgaris patients had recurrent, active disease; the other patients were in remission. Blood sample was collected before corticosteroid treatments in 28 pemphigus foliaceus and 22 pemphigus vulgaris patients. Among pemphigus patients with recurrent, active disease, 9 pemphigus foliaceus and 14 pemphigus vulgaris patients were under systemic therapy at the time of drawing the blood to perform serum B-cell-activating factor measurement. The retrospective nature of the study limited the clinical data concerning severity of the diseases for 27 pemphigus foliaceus and 28 pemphigus vulgaris patients from the case records. For these patients, we evaluated the severity of pemphigus according to the cutaneous and mucosal involvement of defined areas of the body – score 0 (no lesions), score 1 (<25% involvement), score 2 (25%–50%), score 3 (50%–75%) and score 4 (>75%). Thirty eight healthy controls with a median age of 43 years were also recruited in the study.

This investigation was approved by the ethical committee of La Rabta University Hospital. All patients and controls gave their consents for the study.

Pemphigus foliaceus and pemphigus vulgaris patients as well as healthy control were already tested for anti-desmoglein 1 and 3 autoantibodies (MBL, Nagoya, Japan) and the presence of autoantibodies other than anti-desmoglein.[3]

A specific enzyme-linked immunosorbent assay kit was used to measure serum B-cell-activating factor levels (R&D Systems Inc., Minneapolis, USA). Values above the mean ± 2 standard deviation (1168 pg/ml) in control samples were considered as high levels.

Statistical analysis was performed using the Statistical Package for Social Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered statistically significant.

In healthy control, serum B-cell-activating factor levels ranged between 200 and 1200 pg/ml with a mean value of 748 ± 206 pg/ml. Serum B-cell-activating factor mean values did not differ between the three groups (pemphigus foliaceus, pemphigus vulgaris and healthy control), yet we note a P value (P = 0.052) near the threshold of significance. However, after Bonferroni correction, serum B-cell-activating factor levels were significantly higher in pemphigus foliaceus patients (mean level 982 ± 557 pg/ml) than in healthy control, P = 0.046. There was no statistically significant difference between pemphigus vulgaris patients and healthy control [Figure - 1].

Figure 1: Comparison of serum B-cell-activating factor mean levels (pg/ml) in pemphigus patients (pemphigus foliaceus (PF), pemphigus vulgaris (PV)) and in healthy controls (HC). Significant difference (P < 0.05) was observed with pemphigus foliaceus patients when compared to healthy control (serum B-cell-activating factor means are in red lines). BAFF: B-cell activating factor, NS: Not significant

High serum B-cell-activating factor levels were observed in 14 (28%) pemphigus foliaceus and 11 (30.5%) pemphigus vulgaris patients.

In pemphigus foliaceus patients, serum B-cell-activating factor levels were significantly higher in those without corticosteroid treatment (mean level 1229 ± 573 pg/ml) than in healthy control (P < 0.001 by t-test). Moreover, mean serum B-cell-activating factor values were significantly higher in patients with high score disease severity (P = 0.012 by t-test) and in those with the recurrent active disease before re-introduction of corticosteroid or any other treatment (P < 0.001 by t-test) [Table - 1].

Table 1: Mean serum B-cell-activating factor levels according to clinical characteristics of pemphigus patients

In pemphigus foliaceus patients, scores for disease severity were available for seven and twenty cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus foliaceus patients with high serum B-cell activating factor, all (100%) had widespread disease (score of disease severity 3–4) compared to nine of twenty patients (45%) in those with normal serum B-cell-activating factor (P = 0.02 by Fisher's exact test).

In pemphigus vulgaris patients, scores for disease severity were available for 7 and 21 cases with high and low serum B-cell-activating factor, respectively. Among the seven pemphigus vulgaris patients with high serum B-cell activating factor, only 4 (57%) showed severe lesions compared to 6 of 21 (28%) of those with normal serum B-cell-activating factor.

Although serum B-cell-activating factor levels did not correlate with age, stratification of patients according to the mean age revealed that younger pemphigus foliaceus patients had significantly higher levels.

In both groups, there was no significant correlation between serum B-cell activating factor neither with anti-desmoglein 1/desmoglein 3 autoantibodies titers nor with the presence of autoantibodies other than anti-desmoglein.

Unlike previous studies, our findings revealed the presence of a significant difference among autoimmune pemphigus patients and controls.[2],[4]

Matsushita et al. did not find a significant difference between pemphigus or pemphigoid patients and the control group regarding serum B-cell-activating factor levels.[2] Asashima et al. reported a significant difference in bullous pemphigoid, but not in pemphigus vulgaris patients.[4] In this study, we found that serum B-cell activating factor values were significantly higher in pemphigus foliaceus patients than in healthy control. Interestingly, significant associations between serum B-cell-activating factor values, younger age and clinical status (absence of corticosteroid treatment and disease activity) were found only in the pemphigus foliaceus group. In Tunisia, pemphigus has particular epidemiological features: pemphigus foliaceus is the endemic form of the disease; it is predominantly observed in women of the reproductive age group. These patients have common human leukocyte antigen susceptibility alleles which vary from the ones observed in the sporadic form in the north of the country.[5] Thus, B-cell activating factor elevation occurs mainly in patients with Tunisian endemic pemphigus features.

Serum B-cell activating factor mean levels were found to be significantly lower in patients under corticosteroid treatment. This effect is different from that seen in rituximab-treated patients.[6] In this study, we failed to find a significant correlation between anti-desmoglein 1/desmoglein 3 autoantibodies titers and serum B-cell-activating factor, while in systemic lupus erythematosus, a strong association was found between anti-deoxyribonucleic acid antibodies titers and serum B-cell-activating factor values. Moreover, serum B-cell-activating factor levels in Tunisian systemic lupus erythematosus cases are significantly higher compared to those found in Tunisian pemphigus foliaceus patients (2340.72 ± 1000 pg/ml, unpublished data).

The presence of high levels of serum B-cell-activating factor suggests that this cytokine induces the expansion of activated B and T cells and autoantibodies production. This overexpression, significantly observed in the absence of treatment mainly on the earlier onset of pemphigus foliaceus, suggests that serum B-cell-activating factor participated in the proliferation of autoreactive cells, thus enhancing the autoimmune response. Besides, it has been reported that B-cell-activating factor acts on dendritic cells helping them to increase the pro-inflammatory activity of T cells. This is in accordance with the association of high serum B-cell-activating factor levels with high score disease in pemphigus foliaceus. This data may reflect serum B-cell-activating factor contributing to pemphigus pathogenesis.

Interestingly, B-cell-activating factor polymorphism −871C/T is involved in pemphigus foliaceus pathogenesis.[7] Analyzing the association of this polymorphism in our patients and assessing its functional impact are needed to investigate the biological significance of serum B-cell-activating factor elevation in pemphigus foliaceus patients. Targeting B-cell-activating factor with monoclonal antibodies (belimumab) has been approved for systemic lupus erythematosus treatment, but clinical and theoretical arguments for a potential beneficial effect in pemphigus are lacking.[8]

In conclusion, we described the presence of higher levels of serum B-cell-activating factor in pemphigus foliaceus patients. These levels correlated with disease activity in patients without treatment. Because this finding is mainly observed in patients with features of the endemic form of Tunisian pemphigus foliaceus, it needs to be confirmed in other endemic forms of pemphigus within homogeneous and comparable age repartition and disease duration. Answering this question will clarify whether the autoimmune mechanisms through serum B-cell-activating factor varies among pemphigus forms and possibly making the endemic forms distinct.

Acknowledgment

This work was supported by research grant from University of Tunis El Manar to “Immuno-Rheumatology laboratory “ La Rabta Hospital, 1007 Tunis, Tunisia.

Financial support and sponsorship

The study was supported by grants by from Tunis El Manar University, The Tunisian ministry of higher education and scientific research (LR05SP01).

Conflicts of interest

There are no conflicts of interest.

References
1.
Moisini I, Davidson A. BAFF: A local and systemic target in autoimmune diseases. Clin Exp Immunol 2009;158:155-63.
[Google Scholar]
2.
Matsushita T, Hasegawa M, Matsushita Y, Echigo T, Wayaku T, Horikawa M, et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007;16:87-93.
[Google Scholar]
3.
Mejri K, Abida O, Kallel-Sellami M, Haddouk S, Laadhar L, Zarraa IR, et al. Spectrum of autoantibodies other than anti-desmoglein in pemphigus patients. J Eur Acad Dermatol Venereol 2011;25:774-81.
[Google Scholar]
4.
Asashima N, Fujimoto M, Watanabe R, Nakashima H, Yazawa N, Okochi H, et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006;155:330-6.
[Google Scholar]
5.
Abida O, Zitouni M, Kallel-Sellami M, Mahfoudh N, Kammoun A, Ben Ayed M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: Anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009;161:522-7.
[Google Scholar]
6.
Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009;129:2202-10.
[Google Scholar]
7.
Malheiros D, Petzl-Erler ML. Individual and epistatic effects of genetic polymorphisms of B-cell co-stimulatory molecules on susceptibility to pemphigus foliaceus. Genes Immun 2009;10:547-58.
[Google Scholar]
8.
Mahieu MA, Strand V, Simon LS, Lipsky PE, Ramsey-Goldman R. A critical review of clinical trials in systemic lupus erythematosus. Lupus 2016;25:1122-40.
[Google Scholar]

Fulltext Views
357

PDF downloads
100
Show Sections